Literature DB >> 19255799

Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure.

Dirk Westermann1, Alexander Riad, Utz Richter, Sebastian Jäger, Konstantinos Savvatis, Mirjam Schuchardt, Nora Bergmann, Markus Tölle, Dirk Nagorsen, Michael Gotthardt, Heinz-Peter Schultheiss, Carsten Tschöpe.   

Abstract

BACKGROUND: Diastolic heart failure is a rising problem with a high incidence and similar mortality and morbidity compared to patients with systolic heart failure. Nevertheless, the underlying pathophysiology is still debated. AIM: We investigated the effect of pharmacological enhancement of endothelial nitric oxide synthase (eNOS) on experimental diastolic heart failure (DHF).
METHODS: DHF was induced in 60 DAHL salt-sensitive rats by salt diet in 8-week-old animals. 30 were treated with the eNOS enhancer AVE3085 (DHFeNOS) and 30 with placebo (DHF). Rats with normal salt intake served as controls. RESULTS AND
CONCLUSION: Diastolic dysfunction with increased diastolic stiffness constant and increased left ventricular (LV) pressure was analyzed by invasive pressure-volume loop measurements in the DHF group compared to controls. Cardiac hypertrophy as indicated by LV mass measurements by echocardiography, and increased cardiac collagen content as measured by immunohistochemistry were associated with an increased activation state of calcineurin, AKT, ERK(1/2), but not JNK and p38 kinases. Titin isoforms were not altered in this model of DHF. Treatment with AVE3085 significantly increased eNOS mRNA and protein levels in the cardiac tissue and decreases NAD(P)H oxidase subunits p22phox and gp91phox. Diastolic dysfunction was attenuated and cardiac hypertrophy and fibrosis were improved in comparison with untreated DHF animals. This was associated with a normalized activation state of calcineurin, AKT and ERK(1/2). Therefore, we suggest that targeting the NO system might yield a future therapeutic aim for the treatment of DHF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255799     DOI: 10.1007/s00395-009-0014-6

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  26 in total

1.  Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart.

Authors:  Katarzyna A Cieslik; George E Taffet; Signe Carlson; Jesus Hermosillo; Joann Trial; Mark L Entman
Journal:  J Mol Cell Cardiol       Date:  2010-10-23       Impact factor: 5.000

2.  [New therapy concepts for heart failure with preserved ejection fraction].

Authors:  C Tschöpe; B Pieske
Journal:  Herz       Date:  2015-04       Impact factor: 1.443

Review 3.  Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball.

Authors:  Carsten Tschöpe; Sophie Van Linthout; Behrouz Kherad
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

Review 4.  Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.

Authors:  Bharathi Upadhya; Dalane W Kitzman
Journal:  Am J Cardiovasc Drugs       Date:  2017-08       Impact factor: 3.571

5.  Nicorandil suppresses urinary protein excretion and activates eNOS in Dahl salt-sensitive hypertensive rats.

Authors:  Yoshihito Tashiro; Kenji Yogo; Kenichi Serizawa; Koichi Endo
Journal:  Clin Exp Nephrol       Date:  2014-06-22       Impact factor: 2.801

Review 6.  NADPH oxidases and cardiac remodelling.

Authors:  Adam Nabeebaccus; Min Zhang; Ajay M Shah
Journal:  Heart Fail Rev       Date:  2011-01       Impact factor: 4.214

7.  Waon therapy attenuates cardiac hypertrophy and promotes myocardial capillary growth in hypertensive rats: a comparative study with fluvastatin.

Authors:  Hiroyuki Ihori; Takashi Nozawa; Mitsuo Sobajima; Takuya Shida; Yasutaka Fukui; Nozomu Fujii; Hiroshi Inoue
Journal:  Heart Vessels       Date:  2015-12-19       Impact factor: 2.037

8.  Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2.

Authors:  Michael Klaiber; Martin Kruse; Katharina Völker; Juliane Schröter; Robert Feil; Marc Freichel; Andrea Gerling; Susanne Feil; Alexander Dietrich; Juan Eduardo Camacho Londoño; Hideo A Baba; Joel Abramowitz; Lutz Birnbaumer; Josef M Penninger; Olaf Pongs; Michaela Kuhn
Journal:  Basic Res Cardiol       Date:  2010-03-30       Impact factor: 17.165

Review 9.  Heart failure with preserved ejection fraction: emerging drug strategies.

Authors:  Fouad A Zouein; Lisandra E de Castro Brás; Danielle V da Costa; Merry L Lindsey; Mazen Kurdi; George W Booz
Journal:  J Cardiovasc Pharmacol       Date:  2013-07       Impact factor: 3.105

Review 10.  Molecular and cellular basis for diastolic dysfunction.

Authors:  Loek van Heerebeek; Constantijn P M Franssen; Nazha Hamdani; Freek W A Verheugt; G Aernout Somsen; Walter J Paulus
Journal:  Curr Heart Fail Rep       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.